Results 1 to 10 of about 38,450 (306)

[Bispecific antibodies: what future?].

Medecine sciences : M/S, 2009
Monoclonal antibodies have emerged as a very successful class of therapeutic agents. In their native format, monoclonal antibodies are monospecific in that they recognize only one epitope, but their Fc domain also binds to FcfR-expressing cells. Attempts to improve the cytotoxicity of antibodies, particularly in the cancer field, have led to the design
Pèlegrin, André, Robert, Bruno
openaire   +4 more sources

Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method

mAbs, 2023
A challenge when developing therapeutic antibodies is the identification of candidates with favorable pharmacokinetics (PK) early in development. A key determinant of immunoglobulin (IgG) serum half‑life in vivo is the efficiency of pH-dependent binding ...
Thomas Müller, Carolin Tasser, Michael Tesar, Ivica Fucek, Ute Schniegler-Mattox, Joachim Koch, Kristina Ellwanger   +6 more
doaj   +1 more source

Novel Bispecific T-Cell Engagers for the Treatment of Relapsed B Cell Non-Hodgkin Lymphomas: Current Knowledge and Treatment Considerations

Patient Preference and Adherence
Ben Varon,1 Netanel A Horowitz,1,2 Hazim Khatib1 1Department of Hematology and Bone Marrow Transplantation, Rambam Healthcare Campus, Haifa 3109601, Israel; 2Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3109601 ...
Varon B, Horowitz NA, Khatib H
doaj   +2 more sources

Novel mesothelin antibodies enable crystallography of the intact mesothelin ectodomain and engineering of potent, T cell-engaging bispecific therapeutics

Frontiers in Drug Discovery, 2023
Mesothelin is a glypiated, cell-surface glycoprotein expressed at low levels on normal mesothelium but overexpressed by many cancers. Implicated in cell adhesion and multiple signaling pathways, mesothelin’s precise biological function and overall ...
Ida Lin, Peter B. Rupert, Kristina Pilat, Raymond O. Ruff, Della J. Friend, Man Kid Chan, Midori Clarke, Benjamin G. Hoffstrom, Jane Carter, Soheil Meshinchi, Ashok D. Bandaranayake, Christopher Mehlin, James M. Olson, Roland K. Strong, Colin E. Correnti   +14 more
doaj   +1 more source

Serum albumin binding knob domains engineered within a VH framework III bispecific antibody format and as chimeric peptides

Frontiers in Immunology, 2023
BackgroundSerum albumin binding is an established mechanism to extend the serum half-life of antibody fragments and peptides. The cysteine rich knob domains, isolated from bovine antibody ultralong CDRH3, are the smallest single chain antibody fragments ...
Ralph Adams, Callum Joyce, Mikhail Kuravskiy, Katriona Harrison, Katriona Harrison, Zainab Ahdash, Matthew Balmforth, Kelda Chia, Cinzia Marceddu, Matthew Coates, James Snowden, Emmanuel Goursaud, Karelle Ménochet, Jean van den Elsen, Richard J. Payne, Richard J. Payne, Alastair D. G. Lawson, Anthony Scott-Tucker, Alex Macpherson   +18 more
doaj   +1 more source

Bispecific antibody therapies

Hematology, 2023
Abstract Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles.
de Assis, Luiz Henrique, Fassi, Daniel El, Hutchings, Martin   +2 more
openaire   +3 more sources

Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma

Drugs in Context, 2021
Immunotherapy has revolutionized the treatment of cancers. There are several approaches, including naked monoclonal antibodies, antibody–drug conjugates, immune-checkpoint inhibitors and chimeric antigen receptor T cell therapies with important success ...
Omar Castaneda-Puglianini, Julio C Chavez   +1 more
doaj   +1 more source

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors

Biomolecules, 2020
Ligand-targeted toxins (LTTs) are bioengineered molecules which are composed of a targeting component linked to a toxin that induces cell death once the LTT binds its target. Bispecific targeting allows for the simultaneous targeting of two receptors. In
Felix Oh, Jaime F. Modiano, Veronika Bachanova, Daniel A. Vallera   +3 more
doaj   +1 more source

A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration

Cell Reports, 2021
Summary: The dramatically expanding coronavirus disease 2019 (COVID-19) needs multiple effective countermeasures. Neutralizing nanobodies (Nbs) are a potential therapeutic strategy for treating COVID-19.
Xilin Wu, Lin Cheng, Ming Fu, Bilian Huang, Linjing Zhu, Shijie Xu, Haixia Shi, Doudou Zhang, Huanyun Yuan, Waqas Nawaz, Ping Yang, Qinxue Hu, Yalan Liu, Zhiwei Wu   +13 more
doaj   +1 more source

Bispecific antibodies and their applications [PDF]

Journal of Hematology & Oncology, 2015
Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites.
Fan, Gaowei, Wang, Zujian, Hao, Mingju, Li, Jinming   +3 more
openaire   +2 more sources